Evidence map›Paper›PMID 41054531›Full record

ArticleiScience2025

A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity.

Jean Pierre Bikorimana, Nathanael A Caveney, Nehme El-Hachem, Gabrielle A Mandl, John A Capobianco, Daniela Stanga, Jamilah Abusarah, Mark A Hancock, Roudy Farah, Marina P Gonçalves and 7 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Jean Pierre BikorimanaDepartment of Microbiology, Infectious Diseases, and Immunology, Université de Montréal, Montreal, QC H3T 1J4, Canada.
Nathanael A CaveneyCentre for Blood Research, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Nehme El-HachemSainte-Justine Research Centre, Montreal, QC H3T 1C5, Canada.
Gabrielle A MandlDepartment of Microbiology, Infectious Diseases, and Immunology, Université de Montréal, Montreal, QC H3T 1J4, Canada.
John A CapobiancoDepartment of Chemistry and Biochemistry and Centre for NanoScience Research, Concordia University, Montreal, QC H3T 1J4, Canada.
Daniela StangaResearch and Development Branch, Defence Therapeutics Inc., Montreal, QC H4S 1Z9, Canada.
Jamilah AbusarahDepartment of Pharmacology and Physiology, Université de Montréal, Montreal, QC H3T 1J4, Canada.
Mark A HancockSPR-MS Facility, Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada.
Roudy FarahDepartment of Microbiology, Infectious Diseases, and Immunology, Université de Montréal, Montreal, QC H3T 1J4, Canada.
Marina P GonçalvesResearch and Development Branch, Defence Therapeutics Inc., Montreal, QC H4S 1Z9, Canada.
Darryl FalzaranoVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
Mingmin LiaoVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
Glenn HamonicVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
Qiang LiuVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
Simon BeaudoinResearch and Development Branch, Defence Therapeutics Inc., Montreal, QC H4S 1Z9, Canada.
Sebastien TalbotDepartment of Biomedical & Molecular Sciences, Queen's University, Kingston, ON K7L 3J8, Canada.
Moutih RafeiDepartment of Microbiology, Infectious Diseases, and Immunology, Université de Montréal, Montreal, QC H3T 1J4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the recent control of COVID-19, the devastating effects caused by the 3-year pandemic highlight the importance of developing effective vaccines to rapidly address future outbreaks. The present study describes a novel Spike (Sp) protein-based vaccine formulation using the Accum platform. Although Sp-Accum bioconjugation does not alter the overall protein structure, it triggers a substantial antibody titer: i) exhibiting higher specificity toward the S1 domain of Sp, ii) neutralizing Sp-ACE2 interactions, and iii) cross-reacting with various Sp variants. Besides validating the vaccine immunogenicity in rabbits, its administration in a "gold-standard" SARS-CoV-2 hamster model was shown to be safe while accelerating viral clearance without eliciting signs of pathological inflammation in the lungs of infected animals. Altogether, this proof-of-concept study not only demonstrates once again the versatility of the Accum technology in vaccine engineering, but it provides an enabling technology for the rapid development of value-added, protein-based vaccines for future pandemics.

Indexed as

Biological sciencesImmune responseImmunologyNatural sciences

Identifiers

PMID41054531
PMCPMC12496170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.